CYCKLATRAN-M Tablet is a well-formulated combination therapy indicated primarily for the management of abnormal uterine bleeding, dysmenorrhea, and related menstrual irregularities. This medication typically contains Tranexamic Acid and Mefenamic Acid, two active pharmaceutical ingredients that work synergistically to provide effective control of heavy menstrual bleeding and menstrual pain.

Tranexamic Acid, an antifibrinolytic agent, functions by inhibiting the activation of plasminogen to plasmin, an enzyme responsible for breaking down blood clots. By stabilizing clots and preventing excessive bleeding, it significantly reduces the volume and duration of menstrual flow. It acts directly at the site of bleeding, making it highly effective in managing menorrhagia without affecting normal hemostatic processes elsewhere in the body. This targeted mechanism helps patients experience significant improvement in menstrual bleeding without systemic complications.

Mefenamic Acid, on the other hand, is a non-steroidal anti-inflammatory drug (NSAID) that offers both analgesic and anti-inflammatory benefits. It works by blocking prostaglandin synthesis, the chemical compounds responsible for pain and inflammation. Through this mechanism, Mefenamic Acid helps relieve painful cramps, pelvic discomfort, and uterine muscle contractions associated with dysmenorrhea. Together with Tranexamic Acid, it enhances overall patient comfort and improves quality of life during menstruation.

CYCKLATRAN-M Tablet is prescribed for a variety of gynecological conditions where excessive bleeding or severe menstrual pain is a concern. These include primary dysmenorrhea, dysfunctional uterine bleeding, hormone-induced menorrhagia, and other cases of non-structural abnormal uterine bleeding. It may also be used to control bleeding during intrauterine device (IUD) usage or in pre-menopausal women experiencing hormonal imbalances leading to unpredictable cycles.

The dual-action formulation provides fast-acting and long-lasting symptom relief, making it a preferred option for women seeking non-hormonal treatment alternatives. Compared to hormonal therapies, CYCKLATRAN-M offers the benefit of controlling bleeding without affecting ovulation, fertility, or causing hormonal side effects like weight gain or mood changes.

The pharmacokinetic profile of the ingredients ensures rapid absorption and effective plasma concentrations, typically resulting in noticeable symptom relief within a few hours of dosing. The combination therapy allows for reduced dosing frequency, increased patient compliance, and improved outcomes. It is generally recommended to be taken at the onset of menstrual symptoms or heavy bleeding and continued for a few days based on the severity of symptoms and physician guidance.

As with all NSAIDs and antifibrinolytics, proper medical supervision is essential during CYCKLATRAN-M use. Common side effects may include nausea, gastrointestinal discomfort, headache, or mild dizziness. Rare but serious adverse reactions such as hypersensitivity or thromboembolic events should be monitored, especially in women with pre-existing cardiovascular or clotting disorders. The medication is not recommended for individuals with a history of thromboembolism, active peptic ulcer, renal impairment, or uncontrolled hypertension unless specifically directed by a physician.

CYCKLATRAN-M Tablet is manufactured under stringent pharmaceutical standards, ensuring high purity, stability, and consistent therapeutic performance. The formulation is backed by quality control measures that meet both national and international regulatory norms, making it suitable for domestic distribution and export to global markets. Packaging is typically provided in blister strips or tamper-proof containers, with a clear dosage regimen that supports patient adherence.

The tablet is designed to be easy to swallow and is usually taken orally with or after food to minimize gastrointestinal irritation. It is commonly used in hospitals, gynecology clinics, and community healthcare settings, offering reliable support in menstrual health management for adolescent girls and adult women alike. It can be used as a standalone therapy or as part of a broader treatment strategy involving iron supplementation, hormonal regulation, or nutritional support depending on individual case needs.

In third-party manufacturing and export contexts, CYCKLATRAN-M stands out as a high-demand product in the women’s healthcare segment. Its clinically proven components, favorable safety profile, and broad therapeutic indications make it a strategic addition to any pharmaceutical company’s gynecology product line. The growing awareness of menstrual health and increasing preference for non-hormonal, evidence-based treatment options has further driven the demand for combination therapies like CYCKLATRAN-M in both emerging and established healthcare markets.

In conclusion, CYCKLATRAN-M Tablet offers a clinically validated, dual-mechanism solution for heavy menstrual bleeding and painful periods. Its combination of Tranexamic Acid and Mefenamic Acid ensures both control of bleeding and alleviation of pain, without compromising hormonal balance. Manufactured to the highest pharmaceutical standards, it serves as a trusted and effective treatment option for women suffering from menstrual disorders, and represents an important therapeutic choice in modern gynecological care.